Results 111 to 120 of about 23,963 (194)

Neuroprotective crosstalk from vitamin B12 and sphingolipid signaling pathways in therapy for multiple sclerosis. [PDF]

Int Immunol
Kihara Y, Chun J.
europepmc   +1 more source

Pilot Study of Fingolimod Treatment in Neuronal Ceroid Lipofuscinosis Type 1. [PDF]

Neurol Genet
Messina M, Whiteley R, Gan C, Heywood WE, Heslegrave AJ, Keating M, Taylor S, Footitt E, Mills P, Hemingway C, Gissen P, Vecchiato K.   +11 more
europepmc   +1 more source

Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan. [PDF]

Medicina (Kaunas)
Al Anber A, Abu Al Karsaneh O, Abuquteish D, Abdallah O, Issa MA, Sa'adeh M, Kilani D.   +6 more
europepmc   +1 more source

Fingolimod Effects on Motor Function and BDNF-TrkB Signaling in a Huntington's Mouse Model Are Disease-Stage-Dependent. [PDF]

Int J Mol Sci
Nguyen KQ, Rymar VV, Sadikot AF.
europepmc   +1 more source

Oral HPV-Related Epithelial Proliferation during Fingolimod Therapy: First Case Report and Review of the Literature. [PDF]

Head Neck Pathol
Tikkhanarak K, Saepoo J, Handoo N, Lanzel E, Timmons S, Frost R, Hellstein J.   +6 more
europepmc   +1 more source

Clinical and radiological outcomes of directed treatment transitions from Gilenya^® to generic fingolimod. [PDF]

Mult Scler
Patel MA, Punnen TG, Shan KS, McCreary MC, Wright CM, Munoz SB, Hardeman P, Burgess KW, Greenberg BM, Horton LA, Sguigna PV, Tardo LM, Stüve O, Okuda DT.   +13 more
europepmc   +1 more source

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment [PDF]

, 2012
Linssen, W.H.J.P., Oosten, B.W. van, Pouwels, P.J.W., Visser, F., Wattjes, M.P.   +4 more
core   +1 more source

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis. [PDF]

Cost Eff Resour Alloc
Campello CRS, da Costa MGS, Pinto M.
europepmc   +1 more source

Blocking Sphingosine 1-phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease. [PDF]

J Cell Physiol
Skafi N, Pelletier S, Soulage CO, Nahle S, Da Cruz BO, Othmani R, Briolay A, Reibel S, Vitale N, Hamade E, Badran B, Magne D, Buchet R, Stockler-Pinto MB, Fouque D, Mebarek S, Brizuela L.   +16 more
europepmc   +1 more source

Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis. [PDF]

Afr J Lab Med
Kamal DT, Sayed SK, Rageh TA, Rashad B, Badawy ER.   +4 more
europepmc   +1 more source